SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (29658)12/16/1999 12:54:00 AM
From: Henry Niman  Respond to of 32384
 
Since the vote was close and LGND will probably do a Phase IV, I would say that it is POSSIBLE that the approval will be for all CTCL patients, but I would put the chance in the small category.

However, I suspect that oral Targretin will be prescribed for many off label uses including treating patients with early CTCL, advanced breast cancer, advanced head & neck cancer, severe psoriasis, and others with terminal cancer.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News